Verosudil hydrochloride  (Synonyms: AR-12286 hydrochloride)

Verosudil (AR-12286) hydrochloride is the hydrochloride form of Verosudil (HY-16758). Verosudil hydrochloride is a ROCK inhibitor. Verosudil hydrochloride has equal inhibitory activity against ROCK1 and ROCK2 (K_i: 2 nM). Verosudil hydrochloride is less selective for PKA, PKCT, MRCKA, and CAM2A (K_i: 69 nM, 9322 nM, 28 nM, 5855 nM, respectively). Verosudil hydrochloride increases trabecular outflow capacity to reduce intraocular pressure. Verosudil hydrochloride is useful in the study of glaucoma and ocular hypertension^[1][2].

Verosudil (AR-12286) hydrochloride has significant inhibitory activity against both ROCK1 and ROCK2 (K_i: 2 nM)^[1].
Verosudil (0.001-100 μM, 6 hours) hydrochloride dose-dependently reduces the length of actin stress fibers in porcine primary trabecular meshwork cells (PTM)^[1].
Verosudil (0.001-100 μM, 6 hours) hydrochloride reduces the number of focal adhesions in immortalized human trabecular meshwork (HTM) cells^[1].
Verosudil hydrochloride has the ability to disrupt actin stress fibers and focal adhesions in PTM cells and HTM cells (IC₅₀: 924 nM and IC₅₀: 818 nM, respectively)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Verosudil (AR-12286) (30 μL, eye drops, once daily for 3 days) hydrochloride significantly reduces intraocular pressure in Dutch rabbits and Formosan rock monkeys^[1].
Verosudil (10 μL, eye drops, twice daily for five weeks) hydrochloride can reverse the changes in intraocular pressure, trabecular meshwork effective filtration area and morphology in a mouse model of ocular hypertension induced by Dexamethasone (HY-14648) ^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

363.86

C₁₇H₁₈ClN₃O₂S

1414854-44-6

O=C(C(C1=CSC=C1)N(C)C)NC2=CC3=C(C=C2)C(NC=C3)=O.Cl

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Lin CW, et al. Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotensive Agent for the Treatment of Glaucoma. J Ocul Pharmacol Ther. 2018;34(1-2):40‐51.  [Content Brief]

  [2]. Ren R, et al. Rho Kinase Inhibitor AR-12286 Reverses Steroid-Induced Changes in Intraocular Pressure, Effective Filtration Areas, and Morphology in Mouse Eyes. Invest Ophthalmol Vis Sci. 2023 Feb 1;64(2):7.  [Content Brief]